Differential diagnosis

Handbook of Parkinson's Disease, Fourth Edition

Volumn , Issue , 2007, Pages 29-47

  Morgan, John ^a   Sethi, Kapil D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85132515847     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (145)

1. Quirin NP, Luthert P, Hanover M, Marsden CD. Pure akinesia due to Lewy body. Parkinson's disease: a case with pathology. Mov Disord 1989; 4:885-892.
2. Rajput AH. Pathologic and biochemical studies of juvenile parkinsonism linked tochro-mosome 6q. Neurology 1999; 53(6):1375.
3. Klein C, Pramstaller PP, Kis B, et al. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 2000; 48(1):65-71.
4. Polymeropoulos MH. Autosomal dominant Parkinson's disease and alpha-synuclein. Ann Neurol 1998; 44(3 suppl 1):S63-S64.
5. Ross OA, Toft M, Whittle AJ, et al. Lrrk2 and Lewy body disease. Ann Neurol 2006; 59(2):388-393.
6. Paulson HL, Stern MB. Clinical manifestations of Parkinson's disease. In: Watts RL, Koller WC, eds. Movement Disorders: Neurological Principles and Practice. New York: McGraw-Hill, 1997:183-199.
7. Findley LJ, Koller WC. Essential tremor. Clin Neuropharm 1989; 12:453-482.
8. Montgomery EB, Baker KB, Lyons K, Koller WC. Motor initiation and execution in essential tremor and Parkinson's disease Mov Disord 2000; 15(3):511-515.
9. Pahwa R, Koller WC. Is there a relationship between Parkinson's disease and essential tremor? Clin Neuropharm 1993; 16:30-35.
10. Hardie RJ, Lees AJ. Neuroleptic induced Parkinson's syndrome: clinical features and results of treatment with levodopa. Neurology 1987; 37:850-854.
11. Stephen PJ, Williams J. Drug-induced Parkinsonism in the elderly. Lancet 1987; 2:1082.
12. Mutch WJ, Dingwall-Fordyce I, Downie AW, et al. Parkinson's disease in a Scottish city. Br Med J 1986; 292:534-536.
13. Sethi KD, Zamrini EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsych Clin Neurosci 1990; 2:64-66.
14. Giladi N, Kao R, Fahn S. Freezing phenomenon in patients with Parkinsonian syndromes.Mov Disord 1997; 12(3):302-305.
15. Klawans HL, Bergan D, Bruyn GW. Prolonged drug induced parkinsonism. Confin Neurol 1973; 35:368-377.
16. LeWitt PA, Galloway MP, Matson W, et al. Markers of dopamine metabolism in Parkinson's disease. Neurology 1992; 42(11):2111-2117.
17. 18flurodopa PET study. Neurology 1993; 43:552-556.
18. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. Arch Neurol 1964;10:333-359.
19. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988; 38:1031-1034.
20. Dubois B, Slachevsky A, Pillon B, Beato R, Villalponda JM, Litvan I. "Applause sign" helps to discriminate PSP from FTD and PD Neurology. 2005; 64(12):2132-2133.
21. Nuwer MR. Progressive supranuclear palsy despite normal eye movements. Arch Neu-rol 1981; 38:784.
22. Troost B, Daroff R. The ocular motor defects in progressive supranuclear palsy. Ann Neurol 1977; 2:397-403.
23. Vidailhet M, Rivaud S, Gouider-Khouja N, et al. Eye movements in Parkinsonian syndromes. Ann Neurol 1994; 35:420-426.
24. Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997; 62(4):352-356.
25. Masucci EF, Kurtzke JF. Tremor in progressive supranuclear palsy. Acta Neurol Scand 1989; 80:296-300.
26. Schonfeld SM, Golbe LI, Sage JI, Safer JN, Duvoisin RC. Computed tomographic findings in progressive supranuclear palsy: correlation with clinical grade. Mov Disord 1987; 2:263-278.
27. Savoiardo M, Girotti F, Strada L, Cieri E. Magnetic resonance imaging in progressive supranuclear palsy and other Parkinsonian disorders. J Neural Transm Suppl 1994; 42: 93-110.
28. Yagishita A, Oda M. Progressive supranuclear palsy: MRI and pathological findings. Neuroradiology 1996; 38(suppl 1):S60-S66.
29. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive suprauclear palsy. Ann Neurol 1990; 28:547-555.
30. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measures with C-raclopride and positron emission tomography. Ann Neurol 1992; 31:184-192.
31. Fearnley JM, Revesz T, Brooks DJ, Frackowiak RS, Lees AJ. Diffuse Lewy body disease presenting with a supranuclear gaze palsy. J Neurol Neurosurg Psychiatry 1991; 54:159-161.
32. De Bruin VM, Lees AJ, Daniel SE. Diffuse Lewy body disease presenting with supranu-clear gaze palsy, parkinsonism, and dementia: a case report. Mov Disord 1992; 7:355-358.
33. Foster NL, Gilman S, Berent S, et al. Progressive subcortical gliosis and progressive supranuclear palsy can have similiar clinical and PET abnormalities. J Neurol Neuro-surg Psychiatry 1992; 55:707-713.
34. Lees AJ, Gibb W, Barnard RO. A case of progressive subcortical gliosis presenting clinically as Steele-Richardson Olszewski syndrome. J Neurol Neurosurg Psychiatry 1988; 51:1224-1227.
35. Dubinsky RM, Jankovic J. Progressive supranuclear palsy and a multi-infarct state. Neurology 1987; 37:570-576.
36. Winikates J, Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl 1994; 42:189-201.
37. Fink JK, Filling- Katz MR, Sokol J et al. Clinical spectrum of Niemann- Pick disease type C. Neurology 1989;39:1040-1049.
38. Quinn N. Multiple system atrophy. In: Marsden C, Fahn S, eds. Movement Disorders 3. Newton, MA: Butterworth-Heinemann, 1994:262-281.
39. Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112:1171-1192.
40. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele Richardson-Olszewski syndrome). Neurology 1996; 46:922-930.
41. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) report of the NINDS-SPSP international workshop. Neurology 1996; 47:1-9.
42. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969; 32:28-34.
43. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy; an analysis of 100 cases. Brain 1994; 117: 835-845.
44. Van Eecken H, Adams RD, Van Bogaert, L. Striatopallidal-nigral degeneration. J Neuropath Exp Neurol. 1960; 19:159-166.
45. Adams RA, Van Bogaert L, Van der Eecken H. Striato-nigral degeneration. J Neuropathol Exp Neurol. 164; 23:584-608.
46. Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: areview of 203 pathologically proven cases. Mov Disord 1997; 12:133-147.
47. Rajput AH, Kazi KH, Rozdilsky B. Striatonigral degeneration, response to levodopa therapy. J Neuro Sci 1972; 16:331-341.
48. Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992; 55:1009-1013.
49. Lang AE, Birnbaum A, Blair RDG, Kierans C. Levodopa related response fluctuations in presumed olivopontocerebellar atrophy. Mov Disord 1986; 1:93-102.
50. Shy GM, Drager GA. A neurologic syndrome associated with orthostatic hypotension. Arch Neurol 1960; 2:511-527.
51. Wu YR, Chen CM, Ro LS, Chen ST, Tang LM. Vocal cord paralysis as an initial sign of multiple system atrophy in the central nervous system. J Formos Med Assoc 1996; 95(10): 804-806.
52. Bonnet AM, Pichon J, Vidailhet M, et al. Urinary disturbances in striatonigral degeneration and Parkinson's disease: Clinical and urodynamic aspects. Mov Disord 1997; 12(4):509-513.
53. Kirby R, Fowler C, Gosling J, Bannister R. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol Neurosurg Psychiatry 1986; 49:554-562.
54. Valldeoriola F, Valls-Sole E, Tolosa S, Marti MJ. Striated anal sphincter denervation in patients with progressive supranuclear palsy. Mov Disord 1995; 10(5):550-555.
55. Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54:697-702.
56. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease.J Neurol Neurosurg Psychiatry. 2005; 76(2):249-51.
57. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65(12):1863-72.
58. Mega MS, Masterman DL, Benson DF, et al. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology 1996; 47(6):1403-1409.
59. Ala TA, Yang KH, Sung JH, Frey WH. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1997; 62(1):16-21.
60. Rebeiz JJ, Kolodny EH, Richardson EP. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18:220-223.
61. Riley De, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990; 40:1203-1212.
62. Rinne Jo, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration: a clinical study of 36 cases. Brain 1994; 117:1183-1196.
63. Chen R, Ashby P, Lang AE. Stimulus-sensitive myoclonus in akinetic-rigid syndromes. Brain 1992; 115:1875-1888.
64. Litvan I, Agid Y, Gostz C, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathological study. Neurology 1997; 48:119-125.
65. Lang AE, Bergeron C, Pollanen MS, Ashby P. Parietal Pick's disease mimicking cortical-basal ganglionic degeneration. Neurology 1994; 44:1436-1440.
66. Katai S, Maruyama T, Nakamura A, Tokuda T, Shindo M, Yanagisawa N. A case of cor-ticobasal degeneration presenting with primary progressive aphasia Rinsho Shinkeigaku. Clin Neurol 1997; 37(3):249-252.
67. Grisoli M, Fetoni V, Savoiardo M, Girotti F, Bruzzone MG. MRI in corticobasal degeneration. Eur J Neurol 1995; 2:547-552.
68. Nagasawa H, Tanji H, Nomura H, et al. PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration. J Neurol Sci 1996; 139(2):210-217.
69. Neary D, Snowden J, Gustafsson L et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51:1546-1554.
70. Gustaffson L.The clinical picture of frontal lobe degeneration of non-Alzheimer type. dementia 1993; 4:143-148.
71. Pasquier F, Lebert F, Lavenu I, Guillaume B. The clinical picture of frontotemporal dementia: diagnosis and follow-up. Geriatr Cogn Disord 1999;109(suppl 1):10-14.
72. Rinne JO, laine M, Kaasinen V, et al. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 2002; 58:1489-1493.
73. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary intravenous injection of meperidine analogues. Psychiatry Res 1979; 1:249-254
74. Langston JW, Ballard P, Tetrud J, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219:979-980.
75. Tetrud JW, Langston JW, Garbe PL, Ruttenber JA. Early Parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurology 1989; 39:1482-1487.
76. Langston JW, Ballard PA. Parkinsonism induced by 1-methyl-4-phenyl 1,2,3,6-tetra-hydropyridine (MPTP): Implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci 1984; 11:160-165.
77. Langston JW. MPTP-induced Parkinsonism: How good a model is it? In: Fahn S, Marsden CD, Teychenne P, Jenner P, eds. Recent Advances in Parkinson's Disease. New York: Raven Press, 1986:119-126.
78. Huang CC, Chu NS, Song C, Wang JD: Chronic manganese intoxication. Arch Neurol 1989;46:1104-1112.
79. Barbeau A. Manganese and extrapyramidal disorders. Neurotoxicology 1984; 5:113-136.
80. Racette BA, McGee-Minnich L, Moerlein SM, Mink JW, Videen TO, Perlmutter JS. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 2001; 56(1):8-13.
81. Fored CM, Fryzek JP, Brandt L, et al. Parkinson's disease and other basal ganglia or movement disorders in a large nationwide cohort of Swedish welders. Occup Environ Med 2006; 63(2):135-140.
82. Lee MS, Marsden CD. Neurological sequelae following carbon monoxide poisoning: Clinical course and outcome according to the clinical types and brain computed tomography scan findings. Mov Disord 1994; 9:550-558.
83. Miura T, Mitomo M, Kawai R, Harada. CT of the brain in acute carbon monoxide intoxication. Characteristic features and prognosis. AJNR 1985; 6:739-742.
84. Kobayashi K, Isaki K, Fukutani Y, et al. CT findings of the interval form of carbon monoxide poisoning compared with neuropathological findings. Eur Neurol 1984; 23:34-43.
85. Vieregge P, Klostermann W, Blumm RG, Borgis KJ. Carbon monoxide poisoning. Clinical, neurophysiological and brain imaging observations in acute phase and follow up. J Neurol 1989; 239:478-481.
86. Peters HA, Levine RL, Matthews CG, Chapman LJ. Extrapyramidal and other neurological manifestations associated with carbon disulfide fumigant exposure. Arch Neu-rol 1988; 45:537-540.
87. Utti RJ, Rajput AH, Aashenhurst EM, Rozkilsky B. Cyanide-induced Parkinsonism: A clinicopathologic report. Neurology 1985; 35:921-925.
88. Rosenberg NL, Myers JA, Wayne WR. Cyanide-induced Parkinsonism: Clinical, MRI, and 6-fluorodopa PET studies. Neurology 1989; 39:142-144.
89. Guggenheim MA, Couch JR, Weinberg W. Motor dysfunction as a permanent complication of methanol ingestion. Arch Neurol 1971; 24:550-554.
90. Mclean DR, Jacobs H, Mielki BW. Methanol poisoning a clinical and pathological study. Ann Neurol 1980; 8:161-167.
91. Factor SA, Sanchez-Ramos J, Weiner WJ. Trauma as an etiology of Parkinsonism: A historical review of the concept. Mov Disord 1988; 3:30-36.
92. Factor SA. Posttraumatic parkinsonism. In: Stern MB, Koller WC, eds. Parkinsonian Syndromes. New York: Marcel Dekker, 1993:95-110.
93. Critchley M. Medical aspects of boxing, particularly from a neurological standpoint. Br Med J 1957; 1:357-362.
94. Martland HS. Punch drink. J Am Med Assoc 1928; 91:1103-1107.
95. Critchley M. Arteriosclerotic Parkinsonism. Brain 1929; 52:23-83.
96. Fitzgerald PM, Jankovic J. Lower body Parkinsonism: Evidence for a vascular etiology. Mov Disord 1989; 4:249-260.
97. Parkes JD, Marsden CD, Rees JE, et al. Parkinson's disease: Cerebral arteriosclerosis and senile dementia. Q J Med 1974; 43:49-61.
98. Thompson PD, Marsden CD. Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger's disease. Mov Disord 1987; 2:1-8.
99. Mark MH, Sage JI, Walters AS, et al. Binswanger's disease presenting as L-dopa-responsive Parkinsonism: Clinicopathologic study of three cases. Mov Disord 1995; 10:450-154.
100. Hurtig HI. Vascular parkinsonism. In: Stern MB, Koller WC, eds. Parkinsonian Syndromes. New York: Marcel Dekker, 1993:81-93.
101. Krauss JK, Regel JP, Droste DW, Orszag M, Boremanns JJ, Vach W. Movement disorders in adult hydrocephalus. Mov Disord 1997; 12:53-60.
102. Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid hydrodynamics. J Neurol Sci 1965; 2:307-327.
103. Jacobs L, Conti D, Kinkel WR, Manning EJ. Normal pressure hydrocephalus: Relationship of clinical and radiographic findings to improvement following shunt surgery. JAMA 1976; 235(5):510-512.
104. Ahlberg J, Norlen L, Blomstrand C, Wikkelso C. Outcome of shunt operation on urinary incontinence in normal pressure hydrocephalus predicted by lumbar puncture. J Neu-rol Neurosurg Psychiatry 1988; 51:105-108.
105. Waters CH. Structural lesions and parkinsonism. In: Stern MB, Koller WC, eds. Parkin-sonian Syndromes. New York: Marcel Dekker, 1993:137-144.
106. Blocq P, Marinesco G. Sur un cas tremblement parkinsonien hemiplegique symptoma-tique d'une tumeur de pedoncule cerebral. C R Soc Biol 1893; 45:105-111.
107. Samiy E. Chronic subdural hematoma presenting a Parkinsonian syndrome. J Neuro-surg 1963; 20:903.
108. Adler CH, Stern MB, Brooks ML. Parkinsonism secondary to bilateral striatal fungal abscesses. Mov Disord 1989; 4:333-337.
109. Murphy MJ. Clinical correlations of CT scan-detected calcification of the basal ganglia. Ann Neurol 1979; 6:507-511.
110. Lang AE, Koller WC, Fahn S. Psychogenic Parkinsonism. Arch Neurol 1995; 52:802-810. 111.Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987; 2:73-91.
111. Gershanik OS. Early-onset parkinsonism. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. Baltimore: Williams & Wilkins, 1993:235-252.
112. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991; 41:174-181.
113. Snow BJ, Nygaard TG, Takahashi H, Calne DB. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic Parkinsonism. Ann Neurol 1993; 34:733-738.
114. Dobyns WB, Goldstein NNP, Gordon H. Clinical spectrum of Wilson's disease (hepato-lenticular degeneration). Mayo Clin Proc 1979; 54:35-42.
115. Walshe JM, Yealland M. Wilson's disease: The problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 1992; 55:692-696.
116. Topaloglu, H, Gucuyener K, Orkun C, Renda Y. Tremor of tongue and dysarthria as the sole manifestation of Wilson's disease. Clin Neurol Neurosurg 1990; 92:295-296.
117. Sheinberg IH, Sternlieb I, Richman J. Psychiatric manifestations of Wilson's disease. Birth Defects 1968; 4:85-86.
118. Wilson SAK. Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34:295-509.
119. Weilleit J, Kiechl SG. Wilson's disease with neurological impairment but no KayserFleischer rings. Lancet 1991; 337:1426.
120. Demirkiran M, Jankovic J, Lewis RA, Cox DW. Neurologic presentation of Wilson disease without Kayser-Fleischer rings. Neurology 1996; 46(4):1040-1043.
121. Nelson RF, Guzman DA, Grahovaac Z, Howse DCN. Computerized tomography in Wilson's disease. Neurology 1979; 29:866-868.
122. Dettori P, Rochelle MB, Demalia L, et al. Computerized cranial tomography in presymp-tomatic and hepatic form of Wilson's disease. Eur Neurol 1984;23:56-63.
123. King AD, Walshe JM, Kendall BE, et al. Cranial MR imaging in Wilson's disease. Am J Roentgenol 1996;167(6):1579-1584.
124. Steindl P, Ferenci P, Dienes HP, et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997; 113(1):212-218.
125. Saatci I, Topcu M, Baltaoglu FF, et al. Cranial MR findings in Wilson's disease. Acta Radiologica 1997; 38(2):250-258.
126. Snow BJ, Bhatt M, Martin WR, et al. The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991; 54:12-17.
127. Scheinberg IH, Sternlieb I. Wilson's disease: Major Problems in Internal Medicine. Vol 3. Philadelphia: W.B. Saunders, 1984.
128. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson's disease. Medicine 1992; 71:139-164.
129. Sethi KD, Adams RJ, Loring DW, EL Gammal T. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 1988; 24:692-694.
130. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003; 348(1):33-40.
131. Adams P, Falek A, Arnold J. Huntington's disease in Georgia: Age at onset. Am J Hum Genet 1988; 43:695-704.
132. Klawans HL. Hemiparkinsonism as a late complication of hemiatrophy: A new syndrome. Neurology 1981; 31:625-628.
133. Przedborski S, Giladi N, Takikawa S, et al. Metabolic topography of the hemiparkinsonism-hemiatrophy syndrome. Neurology 1994; 44:1622-1628.
134. Waters CH, Faust PL, Powers J, et al. Neuropathology of lubag (X-linked dystonia-Parkinsonism). Mov Disord 1993; 8:387-390.
135. Spitz MC, Jankovic J, Killian JM. Familial tic disorder, Parkinsonism, motor neuron disease and acanthocytosis: A new syndrome. Neurology 1985; 35:366-370.
136. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorder Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18(5):467-468.
137. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42:1142-1146.
138. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56:33-39.
139. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51:745-752.
140. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. Adv Neurol 1990; 53:245-249.
141. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism prospective study. Can J Neurol Sci 1991; 18:275-278.
142. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-184.
143. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57:1497-1499.
144. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinson-ian syndromes in a specialist movement disorder service. Brain 2002; 125:861-870.
145. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4(10):605-610.